Europe Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)

The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030 .

Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies—emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Europe Vaccine Adjuvants Market Overview

The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol “PhytoChol.

Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Vaccine Adjuvants Market Segmentation

The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.

By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.

By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe vaccine adjuvants market.
Highlights key business priorities to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe vaccine adjuvants market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.